WO2009120002A3 - Percutaneous preparation containing donepezil as active ingredient for treatment of dementia - Google Patents
Percutaneous preparation containing donepezil as active ingredient for treatment of dementia Download PDFInfo
- Publication number
- WO2009120002A3 WO2009120002A3 PCT/KR2009/001472 KR2009001472W WO2009120002A3 WO 2009120002 A3 WO2009120002 A3 WO 2009120002A3 KR 2009001472 W KR2009001472 W KR 2009001472W WO 2009120002 A3 WO2009120002 A3 WO 2009120002A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active ingredient
- dementia
- preparation
- donepezil
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a percutaneous preparation containing donepezil as an active ingredient for treatment of dementia. More specifically, the percutaneous preparation comprising donepezil as the active ingredient consists of a matrix layer containing drugs, a support layer for protecting the drugs, and a release layer. The matrix layer containing drugs comprises: donepezil or pharmaceutically acceptable salts thereof as the active ingredient; polyethylene vinyl acetate adhesives including rosin ester resin as a polymer substrate; and a penetration enhancer mixture of at least two kinds selected from the group consisting of pyrrolidone derivatives, C8-18 aliphatic derivatives, triacetin and triethyl citrate. The disclosed percutaneous preparation can increase dementia patient administration compliance and minimize side effects when compared with an oral preparation. Additionally, the percutaneous preparation is easily applied to skin and can release the drugs sustainably for a long time. Also, due to high skin-penetration properties, the preparation can replace conventional oral preparations for treatment of dementia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0026952 | 2008-03-24 | ||
KR1020080026952A KR101454362B1 (en) | 2008-03-24 | 2008-03-24 | Percutaneous absorption preparations for the treatment of dementia containg donepezil as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009120002A2 WO2009120002A2 (en) | 2009-10-01 |
WO2009120002A3 true WO2009120002A3 (en) | 2009-12-23 |
Family
ID=41114447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/001472 WO2009120002A2 (en) | 2008-03-24 | 2009-03-23 | Percutaneous preparation containing donepezil as active ingredient for treatment of dementia |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101454362B1 (en) |
WO (1) | WO2009120002A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2713207C2 (en) * | 2014-12-18 | 2020-02-04 | Айкьюре Фармасьютикал Инк. | Transdermal composition containing donepezil as active ingredient |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2778103C (en) * | 2009-10-21 | 2017-11-07 | Teikoku Seiyaku Co., Ltd. | Donepezil-containing transdermal absorption formulation |
JP5766475B2 (en) * | 2010-03-30 | 2015-08-19 | 日東電工株式会社 | Patch preparation and method for producing the same |
NZ605352A (en) | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
TWI433904B (en) * | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | Donepezil transdermal patch |
KR101054317B1 (en) * | 2011-01-28 | 2011-08-08 | 신신제약 주식회사 | Transepidermal drug delivery system containing rivastigmine |
KR101964295B1 (en) * | 2012-09-05 | 2019-04-01 | 주식회사 한독 | Memantine Transdermal Delivery System Having Reduced Skin Irritation |
KR101485822B1 (en) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | Transdermal drug delivery system comprising donepezil or its salt |
CN106456562B (en) | 2014-02-20 | 2020-01-31 | 安能泰制药有限公司 | Transdermal drug delivery system containing donepezil |
WO2017223402A1 (en) | 2016-06-23 | 2017-12-28 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
EP3490558A1 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Donepezil transdermal delivery system |
AU2017301929B2 (en) | 2016-07-27 | 2023-03-02 | Corium Pharma Solutions, Inc. | Memantine transdermal delivery systems |
JP2020529229A (en) * | 2017-07-26 | 2020-10-08 | コリウム, インコーポレイテッド | Percutaneous delivery system with microporous membranes with solvent-filled pores |
US11173132B2 (en) | 2017-12-20 | 2021-11-16 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
KR102024996B1 (en) | 2017-12-27 | 2019-09-25 | 동아에스티 주식회사 | Percutaneous Absorption Preparation for Treating Dementia Comprising Donepezil |
KR102372630B1 (en) | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | A transdermal preparation comprising a high content of donepezil or a salt thereof |
KR20210133816A (en) | 2020-04-29 | 2021-11-08 | 신신제약 주식회사 | Percutaneous absorption system comprising donepezil |
KR102218593B1 (en) * | 2020-05-13 | 2021-02-22 | 동아에스티 주식회사 | Percutaneous Absorption Preparation Comprising Donepezil with Improved Stability |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11315016A (en) * | 1998-03-03 | 1999-11-16 | Eisai Co Ltd | Preparation or suppository for percutaneous administration containing antidemential agent |
US6677330B1 (en) * | 1999-03-03 | 2004-01-13 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
US20040258741A1 (en) * | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080138388A1 (en) | 2005-02-04 | 2008-06-12 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal Absorption Patch |
-
2008
- 2008-03-24 KR KR1020080026952A patent/KR101454362B1/en active IP Right Grant
-
2009
- 2009-03-23 WO PCT/KR2009/001472 patent/WO2009120002A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11315016A (en) * | 1998-03-03 | 1999-11-16 | Eisai Co Ltd | Preparation or suppository for percutaneous administration containing antidemential agent |
US6677330B1 (en) * | 1999-03-03 | 2004-01-13 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
US20040258741A1 (en) * | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2713207C2 (en) * | 2014-12-18 | 2020-02-04 | Айкьюре Фармасьютикал Инк. | Transdermal composition containing donepezil as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
WO2009120002A2 (en) | 2009-10-01 |
KR101454362B1 (en) | 2014-10-23 |
KR20090101667A (en) | 2009-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009120002A3 (en) | Percutaneous preparation containing donepezil as active ingredient for treatment of dementia | |
JP6077596B2 (en) | Ropinirole-containing patch and its package | |
JP6793648B2 (en) | Transdermal preparation containing donepezil as an active ingredient | |
JP5951637B2 (en) | Transdermal absorption preparation containing rivastigmine | |
JP5001271B2 (en) | New tape formulation | |
EP2687205B1 (en) | Fentanyl transdermal patch | |
JP5823510B2 (en) | Ropinirole-containing patch and its package | |
CA2494361A1 (en) | Hot melt tts for administering rotigotine | |
JP6453481B2 (en) | Patch | |
JP2002363070A (en) | Transdermal patch preparation | |
JP2014177428A (en) | Rotigotine percutaneous absorption type patch formulation containing rosin resin | |
WO2005011662A1 (en) | Adhesive patch | |
WO2006048939A1 (en) | Nonaqueous preparation for percutaneous absorption containing nonsteroidal antiflammatory analgesic | |
KR101868186B1 (en) | Transdermal Patch | |
JP5073124B2 (en) | Noradrenergic / specific serotonergic antidepressant-containing transdermal absorption patch | |
JP2019520413A (en) | Transdermal delivery system containing galantamine or salt thereof | |
CN111542311B (en) | Transdermal absorption preparation containing donepezil for treating dementia | |
JP2022530345A (en) | Percutaneous treatment system | |
WO2014199455A1 (en) | Percutaneous absorption type patch memantine preparation | |
JP5842304B2 (en) | External patch | |
JPWO2017006974A1 (en) | Transdermal patch | |
WO2013183407A1 (en) | Mirtazapine-containing transdermally-absorbable skin-adhesive preparation | |
JP2004067539A (en) | Dermal administration plaster | |
WO2005041967A1 (en) | Transdermal preparations and method for relieving side effects in pergolide therapy | |
JP2018104418A (en) | Rotigotine percutaneous absorption type patch formulation containing antipruritic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09724249 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09724249 Country of ref document: EP Kind code of ref document: A2 |